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Vaccination is one of the most important ways to 
control healthcare costs and stimulate a protective 
immune response against infection in all countries. 
Adjuvant carriers can deposit antigens at the 
injection site, improve their appearance to immune-
competent cells, stimulate T cells, improve antigen 
processing, and increase B cell antibody secretion . 
In the preparation of antibodies and vaccines 
against pathogens, nanoparticles (NPs) are used as 
carriers and adjuvants. 1,2 NPs interact with the 
immune system and modulate its activity, resulting 
in immune stimulation, and have promising medical 
applications. These modulating effects may be 
beneficial or harmful.3,4 Gold nanoparticles 
(AuNPs) have the potential to be a useful tool in the 
development of successful vaccines against 
infectious diseases.5 AuNPs penetrate macrophages 
through receptor-mediated endocytosis and are 
found primarily in lysosomes and the perinuclear 
space, depending on their size and shape.6  
The Rift Valley fever virus (RVFV), a member of 
the genus Phlebovirus in the Bunyaviridae family, 
causes Rift Valley fever (RVF). In the Arabian 
Peninsula and Sub-Saharan Africa, RVFV is a 
mosquito-borne zoonotic pathogen that causes 
serious outbreaks in humans and livestock. Fever is 
a symptom of human diseases, which may 
contribute to retinitis, encephalitis, hemorrhagic 
fever, and occasionally death.7 RVFV can be 
detected using a quantitative reverse transcription 
polymerase chain reaction (qRT-PCR) or an 
enzyme-linked immunosorbent assay that detects 
genomic segments (L, M, S)8 or surface and non-
structural viral proteins9, respectively. These tests 
have a high sensitivity and specificity, but they 
necessitate the transport of unknown samples from 
the field to a laboratory, which increases the risk of 
virus transmission. Zaher et al.10 used unmodified 
gold nanoparticles (AuNPs) that change color in the 
presence of RVFV RNA to create a prototype 
point-of-care diagnostic test specific for RVFV 
detection, resulting in a simple but sensitive assay. 
The nanogold assay yields qualitative results that 
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demonstrate the presence of RVFV RNA in various 
sample types. With a detection limit of 10 RNA 
copies/reaction, the assay demonstrated high 
accuracy and specificity, comparable to quantitative 
reverse transcription polymerase chain reaction. 
The assay result could be determined in 30 minutes 
without the use of any special detection equipment. 
To protect ruminant populations, three approved 
veterinary vaccines against RVFV are used: 
inactivated virus vaccines, live attenuated virus 
vaccines, and alternative virus vaccines (Clone-13 
live and MP-12 live) (OIE, 2015). In the beginning, 
formalin was used to suppress the virus in mice.11 
Beta-propiolactone (PL) is also commonly used in 
the development of viral vaccines as inactivating 
reagent.12 Nearly 100 adjuvants are currently 
available or in production for approximately 400 
vaccines.13 AuNPs are a popular antigen carrier 
used in vaccination and immunization.14 AuNPs are 
commonly used in biomedical research due to their 
unique physicochemical properties, ease of 
preparation, and low toxicity.15 We conducted this 
study to test the activity of spherical and rod-shaped 




Buffalo green monkey cells (Vero) were kindly 
provided by the cell culture department, 
VACSERA, Giza, Egypt. The cell line was 
maintained according to the methods of Abdel-
Gaied et al.16 and dispensed in TC plates and TC 
flasks (SPL-Korea) at 2 × 105 cells/ml. 
 
RVFV strain 
RVFV strain Menya/Sheep/258 was kindly 
provided by Dr. El Karamany, Fotrmer-G.M. of the 
research and development sector, VACSERA, 
Egypt. The infectivity titer was 7.5 log10 /ml. RVFV 
seed stock was prepared according to the method of 
El-Karamany et al.17 
 
Inactivation of RVFV 
RVFV was inactivated by βPL (0.0035 M) supplied 
by Sigma-Aldrich (St. Louis, MO, USA). βPL-
treated RVFV was incubated at 37°C for 2 h with 
continuous stirring. Samples were collected at 15-




Spherical and rod-shaped AuNPs were purchased 
from Nanotech Company (6th October City, Giza, 
Egypt) at 1 mM final concentration and 20 nm size. 




Forty male albino rats (body weight 75-80 g) were 
supplied from Theodore Bilharz Research Institute, 
Giza, Egypt. The rats were housed in both STST 
cages at VACSERA under standard breeding 
conditions and supplied with dry food and tap 
water, at a 12 h light/12 h dark cycle and a 
temperature of 25 °C. 
 
Study design 
The rats were randomly divided into four groups of 
10 each: the negative control (NC) group, rats 
immunized with nonadjuvanted RVF vaccine (the 
Vac group), rats immunized with RVF vaccine 
combined with 40 µM of spherical AuNPs (the 
AuNP-S group), and rats immunized with RVF 
vaccine combined with 40 µM of rod-shaped 
AuNPs (the AuNP-R group). 
 
Immune sera 
Blood samples were collected from the retro-orbital 
plexus of the eye. The samples were kept at 37ºC 
for 30 min for blood coagulation and then kept 
overnight at 4ºC for retraction of the clot. The 
samples were then centrifuged for 15 min at 3500 
rpm in a cold centrifuge (Jouan-ki22-Franc). Sera 
were removed in empty tubes and recentrifuged for 
another 10 min to remove any remaining blood 
clots and red blood cells. The collected sera were 
aliquoted and stored at –80 ºC until use.18 
 
Biochemical analysis 
Serum samples from the immunized groups and 
NCs were processed for evaluation of liver function 
according to measurements of aspartate 
aminotransferase (AST), alanine aminotransferase 
(ALT), and total serum bilirubin (TB) using a 
standard colorimetric kit following the 
manufacturer’s protocol (Biovision, Mountain 
View, CA, USA).19 
 
Immunological studies: cytokine evaluation 
The serum concentration of TNF-α was determined 
by direct enzyme-linked immunosorbent assay 
according to the method of Brouckaert et al.20 
 
Statistical analysis 
All results were expressed as means ± SD. 
Statistical analysis was performed by one-way 
analysis of variance according to the method of 
Dawson and Trapp21 using Statistical Package for 
the Social Sciences software version 25.  




Histological and immunohistochemical studies 
Fresh specimens of liver were taken from the 
control and treated groups. The specimens were 
fixed in 10% formal saline neutral buffer, washed, 
dehydrated in increasing concentrations of alcohol, 
cleared in xylene, and embedded in paraffin wax. 
Sections were prepared at 5-µm thickness and 
stained with hematoxylin and eosin (H&E) for 
histological studies according to the method of 
Drury and Wallington.22 Another set of slides was 
processed for detection of caspase 9 and CD68 as 




Inactivation of RVFV 
RVFV seed stock prepared in the Vero cell line was 
inactivated using 0.0035 M of βPL. Inactivation 
kinetics was determined relative to time (Fig. 1). 
RVFV was completely inactivated within 2 h after 
βPL treatment with a mean depletion of virus 
infectivity titer on the order of 1.2 log10/15 min. 
 
 
Figure 1. Inactivation kinetics of RVFV post 
treatment with βPL to time. 
 
Biochemical analysis 
Compared with rats receiving no treatment (the NC 
group) and rats treated with nonadjuvanted vaccine 
(the Vac group), rats treated with vaccines 
combined with AuNPs exhibited toxic biochemical 
changes, as shown by significant elevations in liver 
enzymatic markers (ALT and AST) and TB (P < 
0.05) after vaccination in the AuNP-S and AuNP-R 
groups (Figs. 2–4). The magnitude of the 
biochemical changes was dependent on the shape of 
the gold NPs: the elevations in ALT, AST, and TB 
were greater in the group treated with AuNP-S 
(spherical NPs) than in the group treated with 
AuNP-R (rod-shaped NPs). The elevations in ALT, 
AST, and TB peaked on day 45 after vaccination 
and then declined. The biochemical changes were 
indicative of damage to the plasmalemma of the 




Levels of TNF-α as a proinflammatory marker were 
detected on day 8 after vaccination and were 
significantly elevated (P < 0.05) in the AuNP-S and 
AuNP-R groups (Fig. 5). The elevation was 
significantly greater in the AuNP-R group than in 
the AuNP-S group and was significantly reduced on 
days 60 and 95. 
 
Histological and immunohistochemical changes 
in liver tissue 
Histological studies 
H&E stain was used to detect hepatic cellular 
changes. The NC group showed normal hepatic 
architecture; the hepatic lobule structure of the liver 
tissue was normal and the central vein was visible. 
The hepatocytes were arranged radially around the 
central vein, the structure of the hepatic sinus was 
clear, and there were no pathological changes (Fig. 
6A). In contrast, the normal lobular structure of the 
liver tissue was changed in all treated rat groups; 
the greatest effect was detected in the AuNP-R 
group. There was a large amount of congestion in 
some hepatic sinuses and the central vein of the 
liver, and the hepatic sinus was clearly dilated. A 
large number of inflammatory cells were infiltrated, 
and the number of Kupffer cells was increased. 
Some hepatocytes showed dense cytoplasm and 
dark nuclei, and others showed vacuolated 
cytoplasm. There were numerous apoptotic figures 
(pyknosis and karyorrhexis), and some binucleated 
cells were observed (Fig. 6B–D). 
 
Immunohistochemical studies 
Immunohistochemical staining of prepared slides 
for detection of caspase 9 apoptosis was scored as 
(−) for normal sections in the NC group, (+3) 
moderate in the Vac group, (+2) mild in the AuNP-
S group, and (+4) highly positive in the AuNP-R 
group (Fig. 7A–D). 
CD68, a widely used monocyte/ 
macrophage lineage marker, was positive in 
all treated groups and showed a weak positive or 
negative reaction in the NC group (Figure 8A–D). 
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Figure 6. (A) Photomicrograhp of rat liver of NC group showing, normal hepatocytes (rounded or polyhedral in shape) 
contain central rounded vesicular nuclei (thick arrows) and sinusoids (curved arrows). Kupffer cells (arrow head) lining 
sinusoids, few cells are binucleated (thin arrows) and endothelial (double arrows) cells lining are noticed between the 
hepatocyte plates  (H & E stain X 400). (B): Photomicrograhp of rat liver of Vac group showing congested blood vessel 
with RBCs (bv) and dialated blood sinusoides (s). There are numerous apoptotic figures (pyknosis; p and karyorrhexis; 
red arrows). Hepatocytes show cytoplasmic vacuolation (arrow head) and kupffer cells (k) are increaesed in number. 
There is inflammatory cell infiltration (bent arrow) in the periportal area. Some hepatocytes are with dense cytoplasm 
and dark nuclei (black arrow) (H&E, X400). (C): Photomicrograhp of rat liver of 40S group showing the central vein 
(cv) and sinusoides (s) are congested with RBCs. The kupffer cells (k) are increaesed in number (H&E X400). (D): 
Photomicrograhp of rat liver of 40R group, showing, inflammatory cell infiltration (bent arrow), congested blood 
vessels (bv), dialated blood sinusoides (s) with increasing number of kupffer cells (k). Some hepatocytes are with dense 
cytoplasm and dark nuclei (arrow). Hepatocytes show vacuolated cytoplasm (arrow head), pyknotic nuclei (p) and few 
hepatocytes are binucleated (plus) (H&E X400).  
 





Figure 7. (A): Immunohistochemical staining of caspase 9 in liver tissues of NC group, (B): Immunohistochemical 
staining of caspase 9 in liver tissues of Vac group showed moderate cytoplasmic caspase 9 positivity (+++), (C): 
Immunohistochemical staining of caspase 9 in liver tissues of 40S group showed mild caspase 9 positivity (++), (D): 
Immunohistochemical staining of caspase 9 in liver tissues of 40R group showed highly positive (++++) for caspase 9. 
 
     
 
Figure 8. (A): Immunohistochemical staining of CD68 in liver tissues of NC group showed weak positive or negative 
reaction. (B): Immunohistochemical staining of CD68 in liver tissues of Vac group mild positive reaction. (C): 
Immunohistochemical staining of CD68 in liver tissues of 40S group moderate positive reaction. (D): 
Immunohistochemical staining of CD68 in liver tissues of 40R group strong positive reaction. 
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DISCUSSION 
Because of their promising chemical and physical 
properties, AuNPs have piqued researchers' interest 
in recent years. AuNPs are noncorrosive and, 
depending on their size and shape, have optical, 
electronic, and biological properties that have made 
them useful in a variety of biomedical applications. 
They have been found to boost immunity.24 Gold 
nanospheres, nanorods, nanobelts, nanocages, 
nanoprisms, and nanostars are some of the shapes 
that AuNPs can be made in.25 The interaction of 
AuNPs with immune cells is extremely important. 
AuNPs can also be used for immunomodulation and 
targeted drug delivery.26 
Nanoparticles (NPs) are perfect for delivering 
antigens, acting as adjuvant platforms, and 
mimicking viral structures, and they play a big role 
in vaccine development. In this study we used 
AuNPs as enhancers to maximize the immune 
response to RVF vaccine and preparation of 
inactivated vaccine was performed using βPL. 
Within 2 hours of treatment, RVFV was completely 
inactivated, and the vaccine potency (ED50) was 
0.0163 ml, which was in line with WHO 
recommendations that the ED50 be less than 0.02 
ml and Soliman et al.27 findings. In previous studies 
Al-Olayan et al.28 reported that βPL had higher 
vaccine potency than formalin and ascorbic acid 
inactivants. This was due to βPL minimal effect on 
the viral epitope configurations that are responsible 
for antigenicity, as well as the fact that βPL had no 
harmful influences on the immune response. Emara 
et al.29 also showed that βPL rapidly inactivated 
rabies virus within 2 hours, with a depletion rate of 
1.8 log10/15 min and an ED50 of >2.5 IU/dose, as 
recommended by WHO.  
The use of AuNPs has been linked to liver 
toxicity and injury, as evidenced by elevated serum 
ALT and AST levels. Hepatocytes produce these 
enzymes, which are released into the bloodstream 
following hepatocellular injury and cholestasis. In 
our study, the levels of these enzymes were higher 
in the groups receiving vaccines combined with 
AuNPs than in the NC group. ALT, AST, and TB 
activities were more elevated after administration of 
AuNP-R than after administration of nonadjuvanted 
vaccine or AuNP-S. Other researchers found 
elevated liver enzymes after being exposed to 
AuNP.30 In another research El Sayed and 
Mohamed31 found that the degenerative effect of 
AuNPs on liver cells significantly increased serum 
levels of ALT and AST in rats treated with 20 µM 
of spherical and 40 µM of rod-shaped AuNPs. In 
addition, when 10 and 50 nM AuNPs were 
administered, AST levels increased when compared 
to controls.32 Similarly, AST and ALT levels were 
significantly higher in animals receiving AuNPs 
compared to the control group two days after 
intervention, according to Doudi and Setorki.33 In 
the current study TNF-α levels were significantly 
higher in all treated groups on day 8 compared to 
the NC group, and significantly lower on days 60 
and 95 (P<0.05). The highest TNF-α level was 
detected after administration of AuNPs-R compared 
with AuNP-S and nonadjuvanted vaccine. Large 
amounts of TNF-α were secreted in response to a 
wide variety of inflammatory stimuli, suggesting a 
potential role for this cytokine in the increased 
activation of the peripheral immune system. In 
accordance with the current findings, Kenichi et 
al.34 concluded that rod-shaped AuNPs uptake into 
cells was as effective as spherical or cubical AuNPs 
uptake and released significant amounts of 
inflammatory cytokines such as TNF-α, IL-6, IL-
12, IL-10, and granulocyte macrophage colony-
stimulating factor (GM-CSF). When rabbits were 
immunized with 50 μg of the HIV-1 Gag p17 
peptide conjugated to 2-nm gold glycol-NPs, the 
proliferation of HIV-specific CD4+ and CD8+ T 
cells increased and secretion of the highly 
functional TNF-α and IL-1β cytokines was induced 
as compared with administration of the 
unconjugated peptide.35 AuNPs combined with 
CpG ODNs considerably enhanced the intracellular 
penetration of NPs into macrophages and the 
secretion of the proinflammatory cytokines TNF-α 
and IL-6, according to Wei  et al.36 Stone et al37 
investigated the relationship between NP size and 
shape and immune response. Liu et al38 reported 
that NPs had a low cytotoxic effect on immune cells 
but significantly stimulated the release of TNF-α, 
which is essential in the removal of abnormal cells. 
In accordance with our findings, Bastús et al39 
found that AuNPs enhanced the induction of 
proinflammatory cytokines such as TNF-α, IL-1, 
and IL-6 in macrophages. Malaczewska40 found that 
mice given AuNPs orally had increased phagocyte 
activity and some changes in lymphocyte 
phenotypes, including a higher percentage of B and 
CD4+/CD8+ double-positive T cells. The lowest 
dose increased the synthesis of the proinflammatory 
cytokines IL-1, IL-2, IL-6, and TNF-α, and had a 
proinflammatory or immune-stimulating effect. 
PVP-AuNPs stimulated the synthesis of 
proinflammatory TNF-α, according to a recent 
study.41 TNF-α and IL-6 are cytokines produced by 
macrophages that affect the systemic inflammatory 
state.42 The current study's histological findings 
largely corroborate the results of biochemical and 
immunological tests. When compared to the NC 
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group, the groups receiving nonadjuvanted vaccines 
and vaccines combined with AuNPs had a lot of 
histological changes in their liver tissues. After 
receiving 40 µM of AuNP-RVF vaccine, damaged 
tissues seemed to return to their usual pattern. 
Histological changes included large numbers of 
infiltrated inflammatory cells. Guo et al43 found that 
giving mice NPs intravenously caused hepatic, 
renal, and pulmonary inflammation, implying that 
NPs have their own mechanisms for causing 
peripheral inflammation. The activation of Kupffer 
cells resulted in an increase in the number of 
Kupffer cells in our study. The activation of 
Kupffer cells has been linked to the toxic potential 
of AuNPs.44 Hepatic sinuses and central vein 
congestion were also caused by the administration 
of AuNPs. Binucleated cells which found in our 
study, indicating the regeneration process, as stated 
by Abdelhalim and Jarrar.45 Also dense cytoplasm, 
dark nuclei, and vacuolated cytoplasm were found 
in some hepatocytes, which may suggest AuNP-
induced acute and subacute liver injury. There were 
a lot of apoptotic figures as well (pyknosis and 
karyorrhexis). These observed changes were 
confirmed by Patlolla et al,46 who stated that as 
compared to the NC, uncoated and PEG-coated 
AuNPs caused major morphological changes, such 
as damage to the central vein; vacuolation in 
hepatocytes, pyknosis, or karyomegaly; and 
condensed nuclei of hepatocytes and necrosis. 
Hepatocyte swelling can be caused by disruptions 
in membrane function caused by AuNPs, resulting 
in a large influx of water and Na+, as well as 
leakage of lysosomal hydrolytic enzymes, 
cytoplasmic degeneration, and macromolecular 
crowding.47 Ibrahim  et al48 concluded that the 
histopathological changes in the liver of AuNPs-
treated mice consisted of steatosis, micro- and 
macrovesicles, cytoplasmic degeneration, necrotic 
foci, activation of Kupffer cells, hemorrhage, and 
infiltration of inflammatory cells were similar to 
our findings. Macrophages and dendritic cells 
absorbed more nanorods, resulting in increased IL-
1β and TNF-α output.49 In line with our findings, 
Doudi and Setorki33 showed that spherical AuNPs 
caused significant changes in the histopathology of 
liver hepatic damage and the aggregation of 
basophilic cells around central vein tissues in all 
treated groups. Another study found that after 
receiving AuNPs, which have direct effects on liver 
function, the liver could be slightly impaired.32 
Hwang et al50 also published research on healthy 
and impaired rodent livers during AuNPs-induced 
hepatotoxicity. Cloudy swelling, vacuolar 
degeneration, hyaline droplets and casts, 
karyorrhexis, and karyolysis were all observed after 
exposure to AuNP doses. Hepatocyte swelling may 
also be caused by a malfunction of the cell 
membrane caused by the large influx of water and 
Na+ caused by AuNPs.51 The pathological changes 
are related to the time between doses: AuNPs 
administered every 48 hours demonstrated possible 
therapeutic benefits without toxicity, while AuNPs 
administered every 24 hours caused significant 
parenchymal changes, leukocyte infiltration and cell 
necrosis.52 Citrate- and pentapeptide-coated AuNPs 
(20 nm, 700 g/kg) were rapidly extracted from the 
bloodstream and accumulated primarily in the liver 
after injection in rats.53 A previous study proposed 
that silymarin-coated AuNPs could be used to treat 
CCl4-induced liver injury and cirrhosis.54 In our 
study, immunohistochemical staining of liver 
sections for detection of caspase 9 apoptosis in NC 
group was rated as (−), (+3) moderate in the Vac 
group, (+2) mild in the AuNP-S group, and (+4) 
strongly positive in the AuNP-R group. These 
results matched those of Baharara et al55, who 
looked at apoptosis in HaCaT cells induced by 
PEG-decorated rod-shaped AuNPs and 
mercaptopropanesulfonate (MPS)-decorated 
spherical AuNPs. As a result, hexagonal and rod-
shaped AuNPs seem to be more likely to cause 
apoptosis than spherical AuNPs. In Calu-3 
epithelial cells, triangular, circular, and hexagonal 
AuNPs caused higher levels of reactive oxygen 
species and proapoptotic markers, such as caspase 3 
and caspase 9, according to Tian et al.56 AuNPs 
induced apoptosis in MCF-7 breast cancer cells 
through the p53, bax/bcl-2, and caspase pathways 
(caspase 3 and 9).57 According to another study, 
quercetin AuNP enhanced caspase activation 
(caspase 3 and 9).58 PEG-coated AuNPs induced 
acute inflammation and neutrophil influx in the 
mouse liver, and the percentage of cells undergoing 
apoptosis in the liver increased on day 7 after 
treatment.59 Caspase 9 acts as an initiator caspase 
that is activated by death-inducing tumor necrosis 
family receptors and cytochrome C, both of which 
are involved in immune and apoptosis signaling.60 
In a variety of pathophysiological settings, 
apoptosis, or programmed cell death, is a critical 
activity in mammalian cells. It is in charge of 
getting rid of unwanted cells.61 CD68 was found to 
be positive in all of the treated groups in the current 
study: it was mildly positive in the Vac group, 
moderately positive in the 40 AuNP-S group, and 
strongly positive in the AuNP-R group. The 
increase in CD68 in the treated groups' serum 
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explained the increase in TNF-α level. This may be 
because the nanorods were targeted to the tissues at 
the same rate as the nanospheres, and Alfranca et 
al.62 came to the same conclusion. The induction of 
TNF-α may be related to the curvature of the 
sphere; the elongated nanorods have a larger 
surface area in contact with the surface of the 
endothelial cells, so more of the antibodies that coat 
the nanorod will attach to receptors on the surface 
of endothelial cells, resulting in more efficient cell 
adhesion and a greater impact on the target 
tissues.63 Rod AuNPs were more easily taken up by 
tumor cells, resulting in particle distribution in the 
tumour.64 Bartucci et al65 corroborated these 
observations. Previous studies have shown that 
AuNP administration causes a mild acute hepatic 
inflammatory response and apoptosis.59 Different 
kinds of NPs are used as delivery mechanisms, and 
they induce alterations in macrophage phenotypes 
that affect the disease's progression. By inhibiting 
regulatory pathways activated by macrophages, 
lipids and polymeric NPs as RNAi vectors can have 
therapeutic effects.66 Adult albino rats exposed to 
AuNPs for a long time developed histological 
changes, with an immunohistochemical analysis 




AuNPs are promising vaccine cellular and humoral 
immune enhancers/adjuvants via different cytokine 
pathways. The immune response depends on the 
shape of the AuNPs, which influences the 
activation of dendritic and other antigen-presenting 
cells. For a better safety measure, further long-term 
studies involving several apoptotic signaling 
pathways and other biomarkers based on 
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